Welcome to 2019! Including reports on a new trial for breast cancer breath tests, the effects of the NHS 10-year plan on the industry, and latest updates on Brexit, here’s what’s hitting pharma headlines in the first week of a brand-new year.
Interested in Star’s innovative outsourcing and resourcing solutions?
Contact Head of Business Development, Ryan Wooller, at email@example.com, or get in touch on 07748 464 079.
On the hunt for a new role, or just curious?
Visit our candidate page, submit your CV to firstname.lastname@example.org, or give our offices a ring!
Horizon scanning: What’s on the agenda for healthcare in 2019 and what does this mean for pharma?
While Brexit is certain to impact the development, manufacture and sale of drugs, the ongoing lack of clarity makes gauging the precise impact very difficult. The following predictions for 2019 are based on those certainties that are available at the time of going to press.
With just a few days to go until the crucial Commons vote on Theresa May’s Brexit plan, a survey has revealed that the UK drugs industry has little confidence that it is a good deal for the sector.
Continuing funding shortages, Brexit uncertainty, regulator moves and regulation reforms: there is no shortage of change facing the sector in 2019.
Cancer Research UK and Owlstone Medical have launched a clinical trial to develop a breath test that could detect cancer at an early stage – the first test of its kind to investigate multiple cancer types.
While you’re here…
…and are interested in our content, why not sign up to our newsletter? It’s just below here.